Low grade endometrial stromal sarcoma of uterine corpus, a clinico-pathological and survey study in 14 cases

被引：43

作者：

Ashraf-Ganjoei T. ^{[1
]}

Behtash N. ^{[1
]}

Shariat M. ^{[1
]}

Mosavi A. ^{[1
]}

机构：

[1] Gynecologic Oncology Department, Vali Asr Hospital, Tehran 14194, Keshavarz Blvd.

来源：

World Journal of Surgical Oncology | / 4卷 / 1期

关键词：

Mitotic Count; Myometrial Invasion; Total Abdominal Hysterectomy; Uterine Sarcoma; Endometrial Stromal Sarcoma;

D O I：

10.1186/1477-7819-4-50

中图分类号：

学科分类号：

摘要：

Background: Endometrial stromal sarcoma (ESS) is a rare disease with probably less than 700 new cases in the USA or Europe per year. The aim of this study was to evaluate the behavior of low-grade endometrial stromal sarcoma (LGESS) in relation to their clinical and pathological features and to identify possible prognostic factors. Patients and methods: Fourteen patients with histologically proven ESS were included in the analysis. Endometrial stromal sarcoma is characterized by proliferations composed of cells with Endometrial stromal cell differentiation. Low-grade endometrial stromal sarcoma has an infiltrating margin and typically show extensive worm-like vessel invasion. Results: The median age was 44.35 ± 6 years. The most common presenting symptom was vaginal bleeding, occurring in twelve patients (86%). Diagnosis was made through Fractional dilatation and curettage in four patients (28.5%). Eight patients had a total abdominal hysterectomy and salpingoophorectomy (57%). Radiotherapy as adjuvant therapy was administered to four patients (28.5%). The median follow-up time was 45.6 months (range 24-84). The median overall survival of the 14 patients was 45.35 ± 21 months (range 20-83). Three of 14 patients demonstrated a recurrence of disease at 9, 72, and 96 months respectively. The recurrent diseases were treated with surgery, chemotherapy, and radiotherapy. No patient died of the disease. Clinico-pathological parameters did not significantly differ between patients with and without recurrence, but patients with no myometrial invasion and low mitotic count <= 5/HPF showed longer disease-free survival. Conclusion: Five-year survival rate was 93%. Survival probabilities were calculated by the product limit method of Kaplan and Meier that showed, patients with no myometrial invasion and low mitotic count <= 5/HPF have longer disease-free survival, but P value was not significant. © 2006 Ashraf-Ganjoei et al; licensee BioMed Central Ltd.

引用

共 20 条

[1]

Boardman C.H., Webb M.J., Jefferies J.A., Low-Grade Endometrial Stromal Sarcoma of the Ectocervix after Therapy for Breast Cancer, Gynecologic Oncology, 79, pp. 120-123, (2000)

[2]

Pink D., Lindner T., Mrozek A., Kretzschmar A., Thuss-Patience P.C., Dorken B., Peter Reichardt: Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: Single center experience with 10 cases and review of the literature, Gynecol Oncol, 101, pp. 464-469, (2006)

[3]

Mesia A.F., Demopoulos I., Effects of leuprolide acetate on low-grade endometrial stromal sarcoma, Am J Obstet Gynecol, 182, pp. 1140-1141, (2000)

[4]

Husseiny G.E., Bareedy N.A., Mourad W.A., Mohamed G., Shoukri M., Subhi J., Prognostic factors and treatment modalities in uterine sarcoma, Am J Clin Oncol, 25, pp. 256-260, (2002)

[5]

Pekindil G., Tuncyurek O., Orguc S., Inceboz U., Kandiloglu A.R., Caglar H., A case of endometrial stromal sarcoma with curvilinear calcification, Gynecologic Oncology, 98, pp. 318-321, (2005)

[6]

Shafi M., Luesley D.M., Jordan J.A., Gynecological Oncology, pp. 120-121, (2001)

[7]

Berkowitz R.S., Goldstein D.P., Uterine cancer, Practical Gynecologic Oncology, pp. 431-432, (2005)

[8]

Feeley K.M., Burton J.L., Wells M., A diagnostic approach to endometrial biopsies: Selected topics, Current Diagnostic Pathology, 6, pp. 13-20, (2000)

[9]

Livi L., Paiar F., Shah N., Blake P., Villanucci A., Amunni G., Uterine sarcoma: Twenty-seven years of experience, Int J Radiat Oncol, Biol, Phys, 57, pp. 1366-1373, (2003)

[10]

Spano J.P., Soria J.C., Kambouchner M., Piperno-Neuman S., Morin F., Morere J.F., Martin A., Breau J.L., Long term survival of patients given hormonal therapy for metastatic endometrial stromal sarcoma, Med Oncol, 20, pp. 87-93, (2003)

← 1 2 →